GSK agreed on September 15, 2026, to acquire full global rights to a trispecific T-cell engager from Chimagen Biosciences for up to $750 million, including upfront and milestone payments.
The experimental therapy is being developed for multiple myeloma, an incurable blood cancer. GSK expects the program to enter Phase 1 trials in 2027.
The molecule is designed to bind T cells while simultaneously targeting two tumor-associated antigens. GSK says this could produce deeper, more durable responses and better tolerability than existing T-cell engagers.
The deal expands GSK’s oncology and multiple-myeloma pipeline and builds on its 2024 agreement with Chimagen for CMG1A46, a dual CD19/CD20 T-cell engager.
The therapy remains experimental:
its clinical effectiveness and safety have not yet been established, and the deal’s milestone payments depend on successful development and commercialization.
Sources:
GSK enters agreement to acquire CMG1A46 from ...
REG - GSK PLC - GSK to acquire T cell-engager for multiple myeloma
GSK strikes up to $750 million deal for cancer-targeting drug
GSK agrees up to USD750 million deal for blood cancer-targeting drug
GSK plc : Berenberg gives a Buy rating
GSK Deepens Blood Cancer Push With $750 Million Trispecific TCE Deal
[PDF] GSK enters agreement to acquire CMG1A46 from Chimagen ...
GSK to Buy Antibody Treatment From Chimagen for Up to $750 Million
GSK News Today | Why did GSK stock go up today?
Pharma Industry News - Latest Updates & Insights
GSK strikes up to $750 million deal for cancer-targeting drug
GSK to pay $300M to license drug it sees as potential lupus treatment
GSK Buys Chimagen Blood Cancer Drug for Up to $750 ...
GSK to shut vaccine factory in Germany, putting 641 jobs at risk